Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Suxamethonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.95 |
| ▸ | MAPT | P10636 | 1/20 | 0.91 |
| ▸ | BLM | P54132 | 1/20 | 0.91 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.62 |
| ▸ | HTR1A | P08908 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.62 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.62 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.62 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Suxamethonium SCHEMBL41537 | 0.97 | ADRA2A (1.00) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| Suxamethonium SCHEMBL2690356 | 0.95 | ADRA2A (0.95) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| Suxamethonium SCHEMBL21356923 | 0.95 | ADRA2A (0.95) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| Suxamethonium SCHEMBL41536 | 0.95 | MAPT (1.00) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| Suxamethonium SCHEMBL1643328 | 0.95 | ADRA2A (0.95) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| Suxamethonium SCHEMBL2821312 | 0.95 | ADRA2A (0.95) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| Suxamethonium SCHEMBL20815392 | 0.93 | MAPT (0.95) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| Suxamethonium SCHEMBL1983256 | 0.93 | MAPT (0.95) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| SCHEMBL11946704 | 0.89 | ADRA2A (0.83) | ADRA2AADRA1AMAPTBLMCYP2C19 | |
| SCHEMBL12560604 | 0.89 | ADRA2A (0.83) | ADRA2AADRA1AMAPTBLMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9645498-B2 | Developer and patterning process using the same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-05-09 | — | — | US | claimed |
| US-20160195813-A1 | DEVELOPER AND PATTERNING PROCESS USING THE SAME | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-07-07 | — | — | US | claimed |
| US-9645498-B2 | Developer and patterning process using the same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20160195813-A1 | DEVELOPER AND PATTERNING PROCESS USING THE SAME | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-9057959-B2 | Developer for photosensitive resist material and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-06-16 | — | — | US | disclosed |
| US-20140377706-A1 | DEVELOPER FOR PHOTOSENSITIVE RESIST MATERIAL AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160195813-A1 | DEVELOPER AND PATTERNING PROCESS USING THE SAME | BMPR1A, RER1, BMPR1B | ADRA2A 3803/4885ADRA1A 2251/4885MAPT 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.